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Primary  canine  hypothyroidism  is  mainly  caused  by  immune-­mediated  destruction  or  idiopathic  
atrophy   of   the   thyroid   gland.   In   the   first   case,   the   thyroid   gland   becomes   progressively  
infiltrated  with  lymphocytes  and  macrophages  (lymphocytic  thyroiditis).  This  leads  to  a  gradual  
destruction  of  thyroid  tissue  and  inevitably  to  reduced  thyroid  hormone  production.  Idiopathic  
thyroid  atrophy  or  degeneration  is  characterized  by  a  loss  of  functional  thyroid  parenchyma,  
which  is  replaced  by  adipose  or  fibrous  connective  tissue.  Its  cause  is  not  yet  clear;;  however  






Figure  1:  Regulation  of  thyroid  hormone  secretion:  The  hypothalamic-­pituitary-­thyroid  axis.  Thyroid  hormones  (e.g.  
T4)  exert  negative  feedback  at  the  pituitary  and  hypothalamic  levels.  Thyroid  stimulating  hormone  (TSH)  causes  
the  synthesis  and  release  of  thyroid  hormones,  which  in  turn  lead  to  a  decrease  in  TSH  (Fig.  A).  In  thyroid  gland  
failure  (hypothyroidism),   the  decreased  concentration  of   thyroid  hormones   leads   to  an   increased  synthesis  and  
secretion  of  TSH  (Fig.  B).  
  
  
Clinical  symptoms  and  clinicopathological  findings  
The  progression  of  the  disease  is  slow,  and  clinical  signs  are  not  expected  to  occur  unless  at  
least  75%  of  the  thyroid  is  affected.  As  thyroid  hormones  have  a  wide  variety  of  physiological  
effects  on  many  organ  systems,  clinical  signs  of  hormone  deficiency  are  broad  and  unspecific.  
Often  they  are  attributable  to  a  decreased  metabolic  rate  such  as   lethargy,  unwillingness  to  
walk,  exercise   intolerance  and  weight  gain  despite  normal  appetite.  Other  common  findings  
are  dermatological  abnormalities,  including  seborrhea,  hair  thinning  and  alopecia,  particularly  
affecting  the  flanks  and  tail,  skin  hyperpigmentation  and  superficial  pyoderma.  Less  common  
signs   include   neuromuscular,   gastrointestinal,   cardiovascular,   ocular   and   reproductive  
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abnormalities.  Most   important   routine  clinicopathologic  changes   include  a  mild  to  moderate  
non-­regenerative  anemia,  hypercholesterolemia  and  hypertriglyceridemia.    
  
Specific  tests  of  thyroid  gland  function  
Clinical   symptoms   as   well   as   changes   in   complete   blood   count   (CBC)   and   serum   blood  
chemistry  often  lead  to  a  first  suspicion.  However,  confirmation  of  the  diagnosis  necessitates  
specific   testing  of   the  thyroid   function  and  confirmation  of   the  diagnosis  can  sometimes  be  
challenging.    
Total  T4  (thyroxine)  concentration  
Determination   of   T4   is   a   useful   screening   test   and   is   particularly   helpful   in   ruling   out  
hypothyroidism  as  approximately  98%  of  the  hypothyroid  dogs  have  low  T4  concentrations.  It  
is  relatively  stable  even  at  room-­temperature  and  can  be  sent  to  outside  laboratories.  However,  
although  low  serum  T4  concentrations  are  intuitively  suggestive  of  hypothyroidism,  it  must  be  
considered  that  low  T4  levels  are  frequently  encountered  in  euthyroid  dogs  with  various  non-­
thyroidal  diseases  (euthyroid  sick  syndrome/nonthyroidal  illness  syndrome)  and  dogs  receiving  
certain  medication  (Table  1).  Moreover,  fluctuations  in  T4  even  below  the  reference  range  also  
occur  in  healthy  dogs.  Also,  one  must  remember  that  certain  breeds  of  dogs,  e.g.  sighthounds,  
Alaskan  sled  dogs,  Dogue  de  Bordeaux  and  Giant  Schnauzer,  have  lower  T4  concentrations  
compared  to  other  breeds.  Therefore,  a  T4  concentration  below  the  reference  interval  cannot  
confirm  hypothyroidism,  however,  a  normal  serum  T4  concentration  can  confirm  normal  thyroid  
gland  function  unless  serum  T4  autoantibodies  are  present  and  interfering  with  the  assay  (see  
below).    
  
Table  1:  Influence  of  certain  drugs  on  thyroid  hormone  parameters  
Drug       T4     fT4   cTSH  
Glucocorticoids   ¯   ¯   =  oder  ¯  
Phenobarbital     =  oder  ¯   =  oder  ¯   =  oder  ­  
Potassium  bromide   =     =     =    
Imepitoin     =   =   =  
Clomipramine   ¯   ¯   =  
Sulfonamides   ¯   ¯   ­  
Carprofen   ¯=   =  oder  ¯   ¯  
Ketoprofen   ¯   =   =  
Deracoxib     =   =   =  
  
  
Serum  free  T4  concentration  
The  metabolically  active  fraction  of  T4,  free  T4  (fT4),  is  widely  acknowledged  to  more  closely  
reflect   the   thyroid   status   than   T4.   Determination   of   fT4   by   equilibrium   dialyses   has   been  
suggested  as  an  alternative,  noninvasive  means  and  by   some  authors   is   considered  more  
sensitive  and  specific  than  the  determination  of  T4.  However,  two  major  considerations  have  
to  be  taken  into  account.  Firstly,  the  equilibrium  dialyses  method  for  determination  of  fT4  is  an  
expensive  analysis  that  is  not  offered  by  many  laboratories  (e.g.  in  Europe  it  is  offered  only  in  
Cambridge,   UK)   and   samples   have   to   be   sent   on   dry   ice.   Secondly,   some   dogs   without  
hypothyroidism,  especially   those  with  euthyroid   sick   syndrome  or  dermatopathies,  or   those  
receiving   glucocorticoids,   may   also   have   decreased   fT4   concentrations.   Therefore   the  
determination  of   fT4,   particularly   in   dogs   from  German-­speaking   countries,   is   not   a   viable  
option   in   confirming   the   diagnosis.   However,   fT4   should   be   determined   if   Anti-­T4  
autoantibodies  (T4AA)  are  suspected  (see  below).    
  
Canine/endogenoues  cTSH  (thyrotropin)  
Endogenous  thyroid  stimulating  hormone   (TSH)   levels   in   the  circulation  are  expected   to  be  
increased  during  states  of  low  T4  (Figure  1).  In  contrast  to  human  medicine,  using  the  currently  
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available   cTSH   assays,   normal   cTSH   concentrations   cannot   exclude   the   presence   of  
hypothyroidism  in  dogs.  Several  reasons  have  been  discussed  to  explain  the  low  sensitivity  of  
only   63-­87%:   secondary   hypothyroidism   (pituitary   problem)  more   common   than   previously  
thought,  physiological  variations,  exhaustion  of  the  pituitary  gland  (TSH-­producing  cells)  after  
longer-­standing   hypothyroid   condition,   existence   of   different   TSH   isoforms   that   are   not  
recognized  by  current  available  cTSH  assays.    
Specificity  of  an  increased  cTSH  is  rather  high  with  values  up  to  98%,  however,  few  exception  
can  lead  to  falsely  increased  values:  treatment  with  sulfonamides,  recovery  phase  of  a  non-­
thyroidal  disease,  after  cessation  of  thyroxine  trial  therapy,  during  trilostane  treatment,  in  dogs  
with  primary  hypoadrenocorticism  before  glucocorticoid  treatment.    
  
Thyroglobulin  Autoantibodies  (TgAA),  T4  and  T3  Autoantibodies  (T4AA,  T3AA)  
The  presence   of   thyroiditis   in  dogs   can  be   detected   by   the  measurement   of   antibodies   to  
thyroid  components  in  the  serum,  usually  antithyroglobulin  antibodies  (TgAAs).  In  contrast  to  
humans   with   thyroiditis,   in   which   antibodies   are   most   commonly   directed   against  
thyroperoxidase   (TPO),   anti-­TPO-­antibodies   are   of   minor   importance   in   dogs.   In   a   large  
number  of  dogs  in  the  United  States,  the  distribution  of  the  two  forms  (lymphocytic  thyroiditis  
and  atrophy)  was  estimated  at  approximately  1:1.  However,  there  seems  to  be  considerable  
variation  among  different  breeds  and  a  tendency  toward  lymphocytic  thyroiditis  at  an  earlier  
age.  The  absence  of  inflammation  is  likely  to  result  in  the  disappearance  of  antibodies  from  
the  circulation  over  time.  What  contribution  this  end-­stage  of  thyroiditis  makes  to  the  50%  of  
canine  hypothyroidism  that  is  antibody-­negative  (idiopathic)  has  not  yet  been  defined.  Although  
a  positive  TgAA  result  is  strong  evidence  of  thyroid  disease,  its  measurement  cannot  be  used  
to  predict  whether  clinically  relevant  destruction  will  occur.  It  has  been  suggested  that  of  TgAA  
positive  dogs,  approximately  15%  become  antibody  negative  over  time  and  remain  euthyroid  
thereafter;;  another  20%  develop  thyroid  hormone  abnormalities  suggestive  of  declining  thyroid  
function  and  about  5%  become  overtly  hypothyroid  within  12-­18  months.  Whether  these  results  
also  hold  true  for  the  general  population  remains  to  be  determined.  Important  to  remember  for  
the  clinician  is  that  determination  of  TgAA  is  not  helpful  in  confirming  the  diagnosis  as  detection  
of  TgAAs  provides  no  information  on  thyroid  function.    
Part  of  TgAAs  also  reacts  against  T3  and  T4  and  these  antibodies  may  interfere  with  hormone  
assays  leading  to  a  spurious  increase  (most  common)  or  decrease  in  the  measured  hormone  
concentration.  T4AA  could  increase  a  low  T4  concentration  into  the  normal  or  high  range  and  
result   in  a  false  diagnosis  of  euthyroidism  in  a  hypothyroid  dog,  which  has  to  be  taken  into  
consideration   in   interpreting   testresults.   If   suspicion   of   hypothyroidism   is   high   but   the   T4  
concentration   is   normal   or   even   increased,   T4AA   should  be  determined   in   addition   to   the  
determination  of  fT4.  Determination  of  fT4  using  equilibrium  dialysis  is  not  influenced  by  the  
presence  of  T4AA.    
  
TSH-­Stimulation  test    
The  TSH  stimulation  test  has  long  been  considered  an  accurate  test,  and  some  authors  still  
recognize   it   as   the   “gold   standard”   for   confirming   the   diagnosis   of   canine   hypothyroidism.  
Determination  of  circulating  T4  before  and  6  hours  after  the  administration  of  exogenous  TSH  
(recombinant   human   TSH,   ThyrogenÒ)   provides   an   assessment   of   the   functional   reserve  
capacity  of   the   thyroid  gland,  with  minimal   to  no  stimulation  expected   in  hypothyroidism.   In  
euthyroid   dogs,   post-­TSH   T4   concentrations   are   expected   to   be   higher   than   30   nmol/L,  
depending  on  the  T4  assay  that  is  used.  An  increase  of  less  than  1.5  times  basal  T4  or  post-­
TSH-­T4   concentration   lower   than   20   nmol/L   are   consistent   with   hypothyroidism.   The   test  
seems  to  be  less  influenced  by  nonthyroidal  illness  and  by  medications  known  to  affect  thyroid  
function,  however,  results  in  the  “grey-­zone”  are  also  possible.  If  testing  cannot  be  delayed,  
the  discriminatory  power  of  the  TSH  stimulation  test  to  differentiate  between  euthyroid-­sick  and  
primary   hypothyroidism,   can   be   improved   if   a   dose   of   150ug   recombinant   TSH   is   used,  
independent  of   the  dog`s  body-­weight.  The  costs  of   the  product   are   rather  high,   however,  
reconstituted  rhTSH  can  be  stored  at  4°C  for  4  weeks  or  −20°C  for  up  to  12  weeks.  This  allows  
multiuse  from  one  vial  making   the   test  somehow  affordable,  although   it   remains  expensive  
compared  to  other  tests.    
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Table   2:   Overview   of   sensitivity,   specificity   and   accuracy   of   specific   parameters   in   the  
diagnosis  of  canine  hypothyroidism  (summarized   from  (Dixon  &  Mooney,  1999;;  Kantrowitz,  
Peterson  et  al.,  2001;;  Boretti  &  Reusch,  2004;;  Ferguson,  2007;;  Scott-­Moncrieff,  2015))  
Parameter   Sensitivity   Specificity   Accuracy  
Low  T4   89  %   75-­82  %   85  %  
Low    fT4  (equ.  Dialyse)   80-­98  %   93-­94  %   95  %  
High  cTSH   60-­87  %   82-­100  %   84  %  
Low  T4  and  high  cTSH   67-­87  %   92-­100  %   82  %  




Ultrasound  of   the  thyroid  glands  can  be  used  as  additional   test  to  support   the  diagnosis.   In  
hypothyroid   dogs   they   are   expected   to   have   a   smaller   volume,   irregular   margins   and   a  
hypoechegenic  parenchyma  compared  to  surrounding  muscles.  A  high-­frequency  ultrasound  
“head”  with  at   least  10MHz  operated  by  an  experienced  ultrasonographer   is  a  prerequisite.  
However,  one  should  be  aware  that  US  cannot  replace  biochemical  examination  and  using  
this  modality  will  not  lead  to  a  final  diagnosis  in  all  cases.    
Scintigraphy  
By   some   authors,   scintigraphic   examination   of   the   thyroid   gland   using   technetium-­99  
(pertechnetate)  has  been  suggested  as  the  most  accurate  technique  for  distinguishing  dogs  
with  primary  hypothyroidism  from  those  with  non-­thyroidal  illness.  However,  results  from  recent  
studies  have  shown  that  there  are  factors,  especially  glucocorticoids  that  can  influence  and  
decrease   uptake,   leading   to   equivocal   results.   Moreover,   due   to   technical   enormous  
requirements,  this  modality  cannot  be  used  in  daily  life  of  a  practitioner.    
  
  
Treatment  and  monitoring    
Synthetic  thyroid  hormone  replacement  in  the  form  of  oral  sodium  levothyroxine  (synthetic  T4)  
is  the  treatment  of  choice.  Recommendation  for   initiation  of   therapy  is  a  starting  dose  of  20  
µg/kg  BW  twice  daily,   lower  doses  may  be  sufficient   in  some  dogs  and  some  authors  also  
recommend  once  daily  dosing.  However,  twice-­daily  dosing  is  associated  with  less  fluctuation  
in  T4  and   lower  peak   concentrations.  Therefore,   once  daily   should  only  be   initiated  only   if  
clinical  signs  are  well  controlled.  A  liquid  formulation  is  also  available,  which  (according  to  the  
manufacturer)  can  be  administered  once  daily  at  a  dosage  of  20  µg/kg  BW  once  daily,  although  
in  selected  dogs  a  change  to  twice  daily  can  be  necessary  to  control  clinical  symptoms.    
In  dogs  with  concurrent  cardiovascular  disease  or  hypoadrenocorticism,  treatment  should  be  
instituted  at  25%  of  the  standard  dose,  with  an  increase  of  25%  every  2  weeks  based  on  clinical  
response  and  post-­pill  testing.    
Gastrointestinal  absorption  of  T4  is  very  low  and  its  bioavailability  is  further  decreased  when  
administered  with   food.  Pilling  on  an  empty  stomach   is  not  a  prerequisite   for  a  therapeutic  
success,  however,  owners  should  be  instructed  to  standardize  time  between  feeding  and  oral  
dosing  and  it  should  be  the  same  time  interval  on  the  day  of  T4  monitoring  as  always.    
Serum  T4  should  be  determined  at  peak  T4  concentration,  which  occurs  about  4-­6  hours  after  
administration.  At  that  time  point  T4  should  be  in  the  high  normal  or  slightly  above  the  reference  
interval.  Serum  TSH  concentrations  should  be  within  the  reference  interval;;  unfortunately,  due  
to  the   low  analytic  sensitivity  of  the  current  cTSH  assays,  they  do  not  allow  identification  of  
oversupplementation.    
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A  positive   response   to   therapy   should  be  observed  within   the   first   4-­6  weeks  after   starting  
treatment.  Improvements  in  physical  activity  and  in  mentation  can  occur  after  1  week,  however  
other  signs,  especially  dermatological  signs  may  take  several  weeks  to  months  to  improve  and  
resolve.    
Reasons   for   treatment   failures   or   incomplete   response   may   be   the   following:   Incorrect  
diagnosis,  concurrent  diseases  such  as  secondary  pyoderma,  inadequate  dosing  (only  once  
daily  treatment,  even  dogs  on  liquid  formulation  may  need  twice  daily  administration),  therapy  
not   long  enough,  poor  owner  compliance,  poor  bioavailability,  un-­registered  product/internet  
pharmacy,  inactive  thyroxine,  poor  gastrointestinal  resorption.    
Thyrotoxic  effects  of  excessive  T4  supplementation  occur  only  rarely  in  dogs  and  among  others  
include  polydipsia,  polyuria,  polyphagia,  panting,  weight  loss,  or  hyperactivity.    
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